Skip to content

Epidaurus · Treatment Guide · Aesthetic & Cosmetic Services

Going abroad for —

Injectable Aesthetics Quality

Botox, fillers, and non-surgical treatment quality

The country comparison

Which countries are best for injectable aesthetics quality

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

  1. 1 Singapore SG 4.5/5 Good Singapore demonstrates comprehensive regulatory oversight through HSA therapeutic product registration, MOH clinic licensing, and SMC practitioner certification, with robust enforcement including 7,351 illegal listing... Full report
    The evidence behind this score 5 cited points
    • HSA mandatory product registration as therapeutic products under Health Products Act with criminal penalties up to SGD 50,000 and/or 2 years imprisonment for unlicensed supply
    • Only licensed medical doctors and accredited dental practitioners authorized to perform; SMC-accredited Certificate of Competence required with written assessment and 80% attendance at lecture/demonstration sessions
    • HSA-registered brands include Botox, Dysport, Xeomin (botulinum toxin) and Juvederm, Restylane, Belotero, EPTQ, Radiesse, Sculptra (fillers); all distributors must meet Good Distribution Practice requirements
    • Hyaluronidase (Hyalase) available at licensed clinics for emergency dissolution of hyaluronic acid fillers; comprehensive patient consultations with contraindication screening standard
    • 2024 enforcement: 7,351 illegal aesthetic product listings removed, 2,868 seller warnings issued; Singapore recognized as adopting more prescriptive approach than regional peers (India, South Korea, Thailand, Malaysia)

    Read the full Singapore report →

  2. 2 United Arab Emirates AE 4.5/5 Good The UAE demonstrates excellent regulatory oversight through the DHA Standards for Non-Surgical Cosmetic Procedures Version 2.1 and the federal EDE registration system, with strong enforcement mechanisms including crim... Full report
    The evidence behind this score 7 cited points
    • DHA Standards for Non-Surgical Cosmetic Procedures Version 2.1 (effective February 2025) establishes comprehensive binding requirements for patient assessment, informed consent, infection control, medication management, emergency response, and clinical audit; violations attract fines up to AED 1 million.
    • Practitioners must demonstrate MD/MBBS, 3+ years aesthetic medicine experience, and 200 documented patient cases via DHA-submitted logbook, supported by formal training from accredited bodies (A4M Dubai, CBAM, ABAM).
    • Multiple FDA/EMA-approved injectable brands available (Botox, Dysport, Xeomin, Juvederm, Restylane, Sculptra, Radiesse, Teosyal, Belotero, Neauvia) through authorized distributors; all products must register with EDE.
    • Tatmeen track-and-trace system recorded 280+ million pharmaceutical transactions as of 2024, providing robust anti-counterfeiting protection; hyaluronidase is commercially available for emergency HA filler reversal.
    • Dubai ranked 6th globally in 2020–2021 Medical Tourism Index and 5th for quality of facilities; JCI-accredited clinics, multilingual staff, and 2025–2026 GDRFA-DHA MOU streamline international patient visa and medical service coordination.
    • Advanced injection techniques (microcannula delivery, ultrasound-guided filler placement/removal, PDO/PLLA/PCL thread lifts, combination protocols) are standard offerings at premium clinics.
    • Follow-up care continuity for international patients is noted as a documented concern—complications such as delayed nodule formation or vascular events may manifest after visitors depart, requiring correction in patients' home countries where original treatment records are unavailable.

    Read the full United Arab Emirates report →

  3. 3 South Korea KR 4.0/5 Good South Korea demonstrates clear regulatory oversight through the MFDS with defined practitioner requirements, good selection of approved injectable products with mostly authentic supply chains, and established safety p... Full report
    The evidence behind this score 6 cited points
    • Ministry of Food and Drug Safety (MFDS) enacts and executes cosmetic regulations with new injectable products requiring clinical data and 4-6 month review as of 2025
    • Only board-certified plastic surgeons (~2,200) can operate on foreigners; MFDS-approved Korean botulinum toxin brands include Nabota (first Korean toxin to receive U.S. FDA approval), Botulax, Liztox, and Innotox
    • Only 12% of dermatology residents had filler injection experience during residency, with expertise primarily gained through post-residency training rather than formal standardized education
    • U.S. Customs and Border Protection seized shipments containing counterfeit Botox and dermal fillers originating from South Korea; hidden tag verification and QR codes introduced to combat counterfeits
    • 2007-2023 litigation analysis of 27 cases revealed high liability findings against practitioners, with skin necrosis and blindness as most common complications; ultrasound-guided hyaluronidase injection emerging as precise complication management approach
    • Korea attracted 1.17 million foreign patients in 2024 with dermatology accounting for 56.6% (705,044 patients); hospitals offer detailed recovery plans, remote follow-ups, and government maintains registration system for institutions certified to serve international patients

    Read the full South Korea report →

  4. 4 Germany DE 4.0/5 Good Germany demonstrates clear regulatory oversight with Botox restricted to licensed physicians and dermal fillers regulated as Class III EU MDR devices with CE marking. BfArM provides robust market surveillance and adve... Full report
    The evidence behind this score 5 cited points
    • Botulinum toxin is prescription-only and restricted to fully licensed physicians; dermal fillers are Class III EU MDR medical devices requiring CE marking with Common Specifications effective June 2023
    • DGBT offers certified 2-day physician-only Botox training courses; specialist plastic surgeons complete 72-month residency programs including 600+ supervised injectable procedures, though no minimum training hours are legally mandated
    • Germany holds 22.3% of Europe's dermal filler market; Merz Pharma (Frankfurt) manufactures Xeomin, Bocouture, Belotero, and Radiesse globally; multiple CE-marked brands widely available
    • Hylase Dessau (hyaluronidase) domestically produced by RIEMSER Pharma GmbH and standard in well-equipped aesthetic practices; BfArM vigilance system requires mandatory adverse event reporting within 30 days
    • Licensed Heilpraktiker (alternative practitioners) legally permitted to inject hyaluronic acid fillers with variable training standards, representing a regulatory gap; absence of standardized follow-up protocols for international patients noted as limitation

    Read the full Germany report →

  5. 5 Israel IL 4.0/5 Good Israel has a clear regulatory framework restricting injectable procedures to licensed medical doctors and dentists, with multiple FDA/EMA-approved brands available through verified supply chains and strong oversight b... Full report
    The evidence behind this score 7 cited points
    • Injectable procedures legally restricted to licensed medical doctors and dentists with Ministry of Health enforcement, representing a significant safety advantage
    • Multiple FDA/EMA-approved products (Botox, Dysport, Juvederm range, Sculptra, HArmonyCa) distributed through authorized channels including official Allergan Aesthetics Israel subsidiary
    • No documented counterfeit injectable issues in regulated clinical settings; dual regulatory system (Ministry of Health for pharmaceuticals, AMAR for medical devices) provides supply chain integrity
    • No mandatory minimum injectable-specific training hours required before independent practice—acknowledged gap compared to UK and other prescriptive regimes; practitioners have general medical licenses only
    • Advanced techniques (microcannula, PDO threads, PRP biostimulators) widely available at leading clinics; practitioners noted internationally for natural-looking results
    • Emergency preparedness protocols (hyaluronidase availability, vascular occlusion management) not visibly standardized or mandated across all practice settings; no published national adverse event registry for injectable aesthetics
    • JCI-accredited hospitals offer multilingual medical tourism services, but injectable-specific follow-up protocols less systematized than dedicated aesthetic medical tourism hubs like South Korea or Turkey

    Read the full Israel report →

  6. 6 Spain ES 4.0/5 Good Spain demonstrates a strong regulatory framework with physician-only practice requirements enforced by AEMPS, a 120-hour EACCME-accredited training program through SEME, and excellent licensed clinics offering EMA-app... Full report
    The evidence behind this score 5 cited points
    • Spain maintains a comprehensive regulatory framework with AEMPS oversight and Royal Decree 1277/2003 requiring physician-only administration of injectable treatments [Expert Guide on Beauty Regulations - CMS Law - 2024]
    • SEME provides a 120-hour accredited Skills Course in Aesthetic Medicine (13.6 SEAFORMEC credits, EACCME-recognized) covering neuromodulators and fillers [SEME Skills Course Accreditation - 2024]
    • EMA-approved botulinum toxins (Vistabel, Azzalure, Bocouture) and CE-marked fillers (Juvederm, Restylane, Teosyal) widely available through authorized medical distributors [Spanish Aesthetic Medicine Market Overview - Chameleon Pharma Consulting - 2024]
    • Major enforcement operations in February 2025 ('Operación Botul/Kalopsia') and May-June 2026 seized over 10,700 combined doses of unauthorized injectables from illegal distributors, with 13+ arrests [Tax Agency Investigation - AEAT/Civil Guard - February 2025; Euro Weekly News - May 2026]
    • Industry data confirms 34% of injectable procedures occur in unlicensed beauty salons rather than licensed medical facilities [Spanish Aesthetic Medicine Market Overview - Chameleon Pharma Consulting - 2024]

    Read the full Spain report →

  7. 7 Turkey TR 4.0/5 Good Turkey demonstrates strong regulatory oversight through multiple specialized agencies, requires 150 hours of specialized training (exceeding typical requirements) with mandatory continuing education, and maintains acc... Full report
    The evidence behind this score 5 cited points
    • Practitioners required to complete approximately 150 hours of theoretical and practical modules for medical aesthetics certification, with mandatory continuing education to maintain certificate validity
    • FDA-approved botulinum toxin products (Botox by Allergan, Dysport by Ipsen) exclusively used by reputable clinics; foreign distributors must register as authorized medical device sales centers
    • Comprehensive medical tourism infrastructure including translation services in multiple languages, integrated treatment packages with consultation and follow-up care, and post-procedure remote monitoring
    • Istanbul recognized internationally for top-tier healthcare services and highly trained medical professionals specializing in injectable aesthetics; modern injection techniques including microcannula available at leading clinics
    • Critical gap: No documented evidence found regarding hyaluronidase availability or injectable-specific emergency protocols for managing vascular complications, despite excellent general safety protocols

    Read the full Turkey report →

  8. 8 Brazil BR 4.0/5 Good Brazil maintains a rigorous ANVISA regulatory framework classifying dermal fillers as Class IV medical devices with full pre-market registration and B-GMP certification requirements. Practitioners—primarily dermatolog... Full report
    The evidence behind this score 4 cited points
    • ANVISA classifies dermal fillers as Class IV medical devices requiring pre-market Registro, B-GMP certification, and clinical evidence; three botulinum toxin brands (Botox, Dysport, Xeomin) and 121+ HA products are ANVISA-registered
    • Brazilian dermatologists performing injectables complete 9 years of combined training (6-year medical degree + 3-year specialty residency) with board certification, CRM registration, and RQE specialist qualification; CFM Resolution 2416/2024 explicitly designates injectables as physician-exclusive acts
    • ANVISA seizures of counterfeit Botox (Lot C3709C3) and Dysport (Lot W07209) in June 2023, plus enforcement actions against companies selling cosmetics as injectables, demonstrate supply-chain vulnerabilities; inspections found unregistered products, expired items, and reused sterile equipment in lower-tier clinics
    • Leading clinics deploy advanced techniques (microcannula, multi-plane layering, ultrasound guidance) and offer 14.2% of their procedures to international patients with English-speaking staff and virtual follow-up care; however, complication surveillance is severely deficient, with 398,830 HA procedures in 2019 reporting zero vision-loss cases—implausibly low compared to Thailand's six cases from far fewer procedures

    Read the full Brazil report →

  9. 9 Poland PL 3.5/5 Moderate Poland has a strong foundational infrastructure through EU regulatory frameworks and active professional societies (PSAD, PTMEiAA), with accredited clinics meeting high safety and quality standards. However, the count... Full report
    The evidence behind this score 4 cited points
    • Poland's regulatory framework includes URPL oversight and EU MDR compliance for fillers, but practitioner requirements remain in a legal gray zone with a January 2026 Ministry communication that is not yet binding legislation [The New Important Position of the Polish Minister of Health - Kieltyka Gladkowski Legal - 2026-01-30]
    • 69% of needle-based aesthetic complications in Poland were caused by practitioners without appropriate qualifications, creating a significant safety concern despite professional guidelines [Complications Associated with Needle-Based Medical Aesthetic Procedures - Beutler et al. - Forum Dermatologicum - 2024]
    • Professional societies (PSAD: 2-year physician training since 2009; PTMEiAA: certified practitioners since 2011) provide structured training, but no nationally mandated minimum-hour requirements exist [About Us - PSAD - 2024]
    • Accredited clinics demonstrate strong outcomes (93% patient satisfaction, NPS >71%) with access to all major brands (Botox, Dysport, Xeomin, Juvéderm, Restylane), hyaluronidase availability, and modern techniques including microcannula approaches [Satisfaction of Consumers Using Innovative Aesthetic Medicine Services in Poland - MINIB Journal - 2024]

    Read the full Poland report →

  10. 10 United States US 3.5/5 Moderate The United States has a comprehensive FDA regulatory framework and excellent product availability (19 approved dermal fillers, 5 botox products) with widespread adoption of advanced microcannula techniques. However, t... Full report
    The evidence behind this score 7 cited points
    • FDA maintains comprehensive regulatory framework with strict pre-market approval and post-market surveillance through MedWatch, with 19 FDA-approved facial dermal fillers and 5 botulinum toxin products available
    • Absence of standardized and regulated training creates significant risks including inconsistent patient outcomes and practitioner competency disparities, with training ranging from 8-hour brief courses to 32-hour programs with no federal requirement for standardized duration
    • No federally mandated continuing education requirements for injectable practitioners, unlike surgical specialties with ongoing recertification
    • Hyaluronidase not evaluated or approved by FDA for dermal filler complications and used off-label without well-established dosage and technique standards
    • No established protocols for international patients; most US aesthetic practices lack standardized procedures for patients requiring follow-up care after returning home
    • Advanced injection techniques like microcannulas widely available and rapidly gaining adoption, representing high practitioner volumes and experience in major metropolitan areas
    • Counterfeit product concerns persist with FDA alerts documenting unsafe counterfeit Botox found in multiple states, with both licensed and unlicensed practitioners administering counterfeit products

    Read the full United States report →

  11. 11 Colombia CO 3.5/5 Moderate Colombia's injectable aesthetics market demonstrates sophisticated capacity at the premium tier but significant heterogeneity across the broader market. The regulatory framework is robust—INVIMA's four-class system, L... Full report
    The evidence behind this score 4 cited points
    • INVIMA operates a 4-class medical device framework; Law 2316 (2023) established criminal penalties of 32-120 years for biopolymer injection; Decree 545 (2024) mandated monthly transaction-level reporting for modeling substances, demonstrating strong regulatory evolution but with documented enforcement gaps (multiple INVIMA alerts 2023-2025 for counterfeits)
    • Practitioners range from SCCP surgeons (12-14 years training) and AsoColDerma dermatologists (3-year residency) to general physicians with brief diploma-level training; no universal mandate for specialized injectable-specific training; pending legislation would require post-graduate specialization
    • Multiple major INVIMA public health alerts (2023-2025) document counterfeit botulinum toxins (INNOTOX, BOTULAX, KOMPLEX-A) and fraudulent fillers (Neuramis, Misfill+); 44 documented adverse events from fraudulent botulinum toxins between early 2023 and mid-2024
    • Botox, Dysport, Xeomin, Juvederm, Restylane, Sculptra, and other premium brands available at accredited clinics; hyaluronidase and advanced injection techniques (microcannula) standard at leading clinics but not universally mandated; Colombia ranks 7th globally for aesthetic surgery quality and received 23,323 international medical tourists to Medellín in 2024 with established bilingual consultations and follow-up protocols

    Read the full Colombia report →

  12. 12 United Kingdom GB 3.5/5 Moderate The United Kingdom offers excellent injectable aesthetics at the regulated premium tier (Harley Street practitioners, Level 7-trained clinicians, rigorous accreditation systems) but faces a significant regulatory gap ... Full report
    The evidence behind this score 5 cited points
    • Botulinum toxin classified as POM requiring qualified prescriber with face-to-face consultation; dermal fillers unregulated, permitting any person to administer regardless of training
    • Level 7 Diploma in Clinical Aesthetic Injectable Therapies available at 600 hours TQT with JCCP/BCAM accreditation, but qualification is voluntary with no legal requirement
    • MHRA and Border Force seized over 4,700 vials of unlicensed botulinum toxin since May 2023; 41 botulism hospitalizations in summer 2025 linked to mislabeled 185% potency Korean products
    • Harley Street concentrates 40% of UK aesthetic procedures and hosts internationally award-winning clinics with advanced techniques (microcannula, bio-stimulators); Save Face accreditation enforces 116-point safety assessment and emergency preparedness
    • Estimated 3 unregulated practitioners for every regulated one (approximately 18,000+ unlicensed providers); unregulated sector lacks consent documentation, training records, and emergency hyaluronidase access

    Read the full United Kingdom report →

  13. 13 Hungary HU 3.5/5 Moderate Hungary maintains EU-standard product safety through Class III MDR classification and robust regulatory oversight, with strong clinical outcomes at leading Budapest clinics supported by international accreditation and... Full report
    The evidence behind this score 5 cited points
    • Dermal fillers classified as Class III medical devices under EU MDR Annex XVI with mandatory CE marking, notified body conformity assessment, and NNGYK registration; botulinum toxin restricted to prescription-only medicine
    • No nationally mandated injectable-specific training hours or dedicated injectable aesthetics legislation; practitioner expertise varies by clinic tier based on voluntary qualifications
    • Hyaluronidase medically available but not universally mandated at treatment sites, creating variable emergency preparedness across market
    • Leading clinics hold ISO 9001:2015 and EBOPRAS accreditation with high international patient satisfaction (4.9/5 verified reviews, WhatClinic Award 2024)
    • Multiple premium CE-marked brands available through authorized EU distribution channels; Budapest serves as regional distribution hub

    Read the full Hungary report →

  14. 14 India IN 3.5/5 Moderate India operates a regulatory framework for injectable aesthetics that is well-defined on paper—with CDSCO classification of injectables as drugs, Schedule H pharmaceutical controls, and IADVL professional guidelines—bu... Full report
    The evidence behind this score 8 cited points
    • CDSCO May 2026 notice classified injectable products as pharmaceutical drugs requiring licensed practitioner administration and approved products under Schedule H controls
    • IADVL published comprehensive guidelines mandating informed consent, pre/post photography, sterile technique, and pre-treatment contraindication screening for botulinum toxin
    • REDEFINE REJUVENATION multicenter study across 9 Indian specialist centers found 90% of filler patients achieved 'much improvement' or 'very much improvement' at follow-up
    • Multiple CDSCO-approved injectable brands available through authorized pharmaceutical channels: Botox, Dysport, Juvederm, Restylane, and Belotero
    • IADVL formally documented at least 5 deaths from procedures performed in unregulated settings, indicating serious enforcement gaps and safety risks in the parallel market
    • No nationally mandated minimum training-hour requirement; any MBBS graduate can obtain injectable certification through private weekend courses
    • Hyaluronidase available at qualified clinics for emergency filler reversal but not a nationally mandated stocking requirement
    • Advanced injection techniques—microcannula, PDO threads, combination protocols—routinely offered at premium centers in Delhi, Mumbai, Bengaluru, and Chennai

    Read the full India report →

  15. 15 Japan JP 3.5/5 Moderate Japan maintains a comprehensive regulatory framework (PMDA/MHLW) with strict product approval, physician-only injector requirements, and exceptional safety outcomes (0.0041% serious complication rate from 299,413 sess... Full report
    The evidence behind this score 5 cited points
    • PMDA/MHLW comprehensive regulatory framework with post-market surveillance; only Botox Vista, Juvederm Vista, and Restylane formulations MHLW-approved domestically
    • Zero mandatory injectable-specific training hours required at national level, though training available through Allergan Medical Institute, IFAAS, and AMWC Japan
    • Nationwide study: 0.0041% serious complication rate (12 complications from 299,413 hyaluronic acid injection sessions), attributed to standardized protocols and anatomical education
    • Physician-only injector rule (6-year medical school + 2-year mandatory clinical training) eliminates non-physician pathways, but no mandatory continuing education in injectables
    • Limited international patient protocols with language barriers; hyaluronidase available at premium clinics (¥20,000-¥55,000) but not universally mandated; budget chains (350+ locations) using non-approved products outside adverse event compensation system

    Read the full Japan report →

  16. 16 Mexico MX 3.5/5 Moderate Mexico maintains a clear regulatory framework (COFEPRIS) with multiple approved injectable products and world-class facilities at the premium tier, yet critical gaps prevent a higher score. No mandatory minimum inject... Full report
    The evidence behind this score 5 cited points
    • COFEPRIS provides pharmaceutical registration for botulinum toxins (Botox, Dysport, Xeomin) and medical device oversight; 2025 abbreviated pathway improves access to FDA/EMA-approved products
    • No nationally mandated injectable-specific training minimums despite multiple voluntary certification programs (CBAM 90+ hours, IPPC 544 hours); nurses, dentists, and medical assistants legally permitted to inject
    • Multiple FDA/EMA-approved brands available through authorized channels with cold chain maintenance; however, COFEPRIS closed 78 irregular establishments since 2022 for counterfeit/expired products; estimated 60% of informal-channel products may be stolen or falsified
    • JCI-accredited facilities maintain high safety standards; no national regulatory mandate for hyaluronidase availability; 8% complication rate documented in 2023 study of North Americans; systematic underreporting indicated by absence of published vascular occlusion case series despite 170,515 estimated HA filler procedures in 2019
    • Excellent medical tourism infrastructure with bilingual staff, concierge services, and geographic proximity to US; 40–70% cost advantage vs US at premium tier

    Read the full Mexico report →

  17. 17 Malaysia MY 3.5/5 Moderate Malaysia has a clear regulatory framework (LCP system) with defined practitioner training, examination requirements, and a broad selection of approved injectable products. Leading clinics demonstrate expertise in Asia... Full report
    The evidence behind this score 6 cited points
    • LCP system requires theory and practical examinations for botulinum toxin and filler administration, plus 2 years of private practice before eligibility, creating a multi-stage credentialing filter
    • Approximately 783 doctors hold active LCP Chapter 1 certificates as of mid-2025, but specialist dermatologist estimates thousands of unlicensed practitioners also perform injectable procedures
    • Broad product selection includes Botox, Dysport, Xeomin, Nabota for botulinum toxin and Juvederm, Restylane, Teosyal, Belotero, Radiesse, Sculptra for fillers, with MOH cold-chain audits and lot tracking at licensed facilities
    • No nationally mandated protocol for vascular occlusion emergencies; hyaluronidase available at leading clinics but not required system-wide; no unified injectable-specific complication reporting registry
    • Health Ministry recorded 306 complaints about unregistered aesthetic premises in 2023 and identified thousands of unlicensed practitioners; active black market for counterfeit injectables via social media
    • Strong medical tourism infrastructure: MHTC support, 1.6 million international healthcare travelers in 2024, 90-day visa-free entry, English-speaking private sector, dedicated international patient departments at premium clinics

    Read the full Malaysia report →

  18. 18 Thailand TH 3.0/5 Moderate Thailand's injectable aesthetics sector presents a moderate profile with significant regulatory gaps offsetting capabilities at leading facilities. While top-tier hospitals offer FDA-approved products, experienced pra... Full report
    The evidence behind this score 5 cited points
    • Neither the Medical Devices Act nor the Cosmetics Act specifically addresses aesthetic medicine, creating a regulatory void for injectable procedures
    • No mandatory specialized training requirement exists specifically for injectable aesthetics; any licensed doctor can legally perform these procedures
    • Counterfeit Botox is documented as a common issue in Asia and Southeast Asia, including Thailand, though leading clinics maintain authentication protocols
    • Safety protocols and hyaluronidase availability are not standardized across all clinics; emergency preparedness varies significantly by facility
    • Leading facilities (Bumrungrad, major hospitals) have JCI accreditation, experienced practitioners, FDA-approved products, and comprehensive medical tourism infrastructure

    Read the full Thailand report →

  19. 19 Jordan JO 3.0/5 Moderate Jordan has a basic regulatory framework explicitly governing injectable aesthetics and requiring licensed practitioner status, but enforcement is documented as inconsistent due to inspection staff shortages, allowing ... Full report
    The evidence behind this score 5 cited points
    • Regulation No. 99/2016 explicitly reserves Botox, fillers, PRP, and mesotherapy for licensed medical practitioners, with Ministry of Health authority to close violators, but enforcement is characterized as inadequate and inconsistent due to inspection staffing shortages [Cosmetic Clinics Regulations Get A Nip And Tuck - Mondaq - 2021]
    • 2022 peer-reviewed survey of 42 Jordanian dermatology residents found 64.3% had received no cosmetic training or procedures during residency, with only 7.2% expressing satisfaction with training standards, revealing systemic gaps in injectable-specific competency [Cosmetic Dermatology Training Perspectives during Residency - PubMed - 2022]
    • No mandatory injectable-specific certification program equivalent to UK Level 7 or South Korea's aesthetic medicine board exists; a licensed physician of any specialty may perform Botox and fillers without formal hands-on injectable training beyond their medical degree [report analysis]
    • Leading Amman clinics offer wide portfolio of FDA/CE-approved products (Juvederm, Restylane, Belotero, Profhilo, Radiesse, Sculptra, both Allergan Botox and Dysport) with advanced techniques (microcannula, cannula/needle combination, MDCodes) at specialist facilities like Abdali Hospital (JCI/HCAC accredited) [Dermal Fillers Amman - Dr. Alghoul Clinic - 2024; Face & Neck Tightening Treatments - Dr. Hannah Clinic - 2024]
    • Standalone aesthetic clinics lack formal protocols specifically designed for medical tourist patients with limited follow-up windows, with no standard revision guarantees or dedicated international patient pathways outside hospital systems [Medical Tourism Implications section]

    Read the full Jordan report →

Reading the field

What separates a good programme from a dangerous one

Every country above is graded against this published scale — the same 1–5 rubric for injectable aesthetics quality, top to bottom. How we score →

  1. 5/5 Excellent

    - Comprehensive regulatory framework specifically governing injectable aesthetics with regular enforcement - Practitioners required to have specialized training (40+ hours) in injection techniques with mandatory continuing education - Multiple FDA/EMA approved injectable brands available through verified authentic supply chains - Standardized safety protocols including mandatory hyaluronidase availability and complication management - International reputation for natural-looking results and low complication rates - Established protocols for international patients with follow-up care arrangements - Advanced injection techniques widely available (microcannula, threading, etc.)

  2. 4/5 Good

    - Clear regulatory oversight of injectable treatments with defined practitioner requirements - Specialized injection training required (20-40 hours) with some continuing education - Good selection of approved injectable products with mostly authentic supply chains - Basic safety protocols in place with emergency response capabilities - Positive reputation for injectable treatments with documented good outcomes - Some accommodation for international patients seeking injectable treatments - Modern injection techniques available at leading clinics

  3. 3/5 Moderate

    - Basic regulatory framework covering injectable treatments with inconsistent enforcement - General medical training required but limited injectable-specific certification (under 20 hours) - Moderate selection of approved products with occasional counterfeit concerns - Standard medical safety protocols but limited injectable-specific emergency preparedness - Mixed reputation with variable practitioner skill levels - Limited specific protocols for international injectable patients - Traditional injection techniques primarily used

  4. 2/5 Poor

    - Minimal regulatory oversight of injectable aesthetic treatments - No specific injectable training requirements beyond basic medical licensing - Limited product selection with significant counterfeit product concerns - Basic safety measures without injectable-specific complication management - Poor reputation due to complications or unnatural results - No specific accommodation for medical tourists seeking injectable treatments - Outdated techniques and limited product knowledge

  5. 1/5 Very Poor / Unavailable

    - No regulatory framework governing aesthetic injectable treatments - Unlicensed practitioners commonly performing injectable procedures - Widespread availability of counterfeit or unapproved injectable products - No safety protocols or emergency response for injectable complications - High complication rates or poor aesthetic outcomes reported - No infrastructure for international patients seeking injectable treatments - Dangerous or inappropriate injection practices documented

The reports

The full country reports under this lens

Each destination we have assessed has a full, cited report — the detailed analysis behind its score. The verdict is free; the report is the depth.

Clinics & providers

The clinics our research names

Named hospitals, clinics and centres cited across these findings — each carrying the specialties our reports record. Follow one to the reports behind it.

References

The sources behind these assessments

The distinct sources cited across these published reports — every finding carries its own citations; this is the union, each linking back to the reports that lean on it.

  1. Untitled source coepris.slpsalud.gob.mx/index.php/372-alerta-cofepris-por-botox-2 Cited in Injectable Aesthetics Quality in Mexico
  2. Untitled source www.aestheticcosmeticphysicians.org Cited in Injectable Aesthetics Quality in United States
  3. Untitled source aaamed.org/onsitecourselp Cited in Injectable Aesthetics Quality in Thailand
  4. Untitled source aaams.net Cited in Injectable Aesthetics Quality in Thailand
  5. Untitled source abamcosmeticsurgery.com Cited in Injectable Aesthetics Quality in United States
  6. Untitled source abamedicine.com/course/asia-thailand-aesthetic-medicine-training-certification-course-step-1-bangkok-7 Cited in Injectable Aesthetics Quality in Thailand
  7. Untitled source abamedicine.com/venue/thailand-abam-regional-training-center Cited in Injectable Aesthetics Quality in Thailand
  8. Untitled source academic.oup.com/asj/article/45/7/NP137/7985873 Cited in Injectable Aesthetics Quality in India
  9. Untitled source aestheticairways.com/botox Cited in Injectable Aesthetics Quality in Turkey
  10. Untitled source aestheticinstituteindia.com Cited in Injectable Aesthetics Quality in India
  11. Untitled source aestheticmedicaltraining.com/product/albuquerque-nm-amet-basic-injectable-filler Cited in Injectable Aesthetics Quality in Mexico
  12. Untitled source agepsa.cdmx.gob.mx/comunicacion/nota/alerta-sanitaria-sobre-la-falsificacion-del-producto-botox-toxina-botulinica-tipo-solucion-inyectable-100u Cited in Injectable Aesthetics Quality in Mexico
  13. Untitled source americanhealthtourism.org/medical-tourism-mexico Cited in Injectable Aesthetics Quality in Mexico
  14. Untitled source asiaactual.com/thailand-3/medical-device-registration Cited in Injectable Aesthetics Quality in Thailand
  15. Untitled source asiaaestheticmedicine.com/board-certification.php Cited in Injectable Aesthetics Quality in United States
  16. Untitled source asianmail.in/2024/10/25/iadvl-jk-branch-gmc-srinagar-host-aesthetics-workshop Cited in Injectable Aesthetics Quality in India
  17. Untitled source assets.imcas.com/congresses/india2025/en_program.pdf Cited in Injectable Aesthetics Quality in India
  18. Untitled source aurabangkokclinic.com/en/blog/best-filler-brands Cited in Injectable Aesthetics Quality in Thailand
  19. Untitled source aurabangkokclinic.com/en/blog/botox-injection-in-bangkok Cited in Injectable Aesthetics Quality in Thailand
  20. Untitled source bangkokhealthservice.com/medical-package Cited in Injectable Aesthetics Quality in Thailand
  21. Untitled source beautupclinic.com/cosmetic-surgery-vacation-in-thailand Cited in Injectable Aesthetics Quality in Thailand
  22. Untitled source beautupclinic.com/dermal-fillers Cited in Injectable Aesthetics Quality in Thailand
  23. Untitled source bioregservices.com/blog/regulation-of-cosmetic-products-in-israel Cited in Injectable Aesthetics Quality in Israel
  24. Untitled source cdn.who.int/media/docs/default-source/searo/india/antimicrobial-resistance/ipcguidelines-web-sep2020.pdf Cited in Injectable Aesthetics Quality in India

Explore the source archive →

In plain language

Start exploring the knowledge base

The field's shorthand our reports use, sized by how often it comes up. Follow any term to its full entry and the reports that use it.

For readers weighing this decision

Ways to read the evidence

The verdict is always free. A membership opens the full analysis and every cited source — this specialty, the whole library, or everything for good.

  • One specialty · annual

    Aesthetic & Cosmetic Services

    $49.00 / year

    $49.00/year

    Every report in this specialty — full analysis and every cited source — as each is published.

    Take this specialty

  • Full library · annual

    The whole library

    $199.00 / year

    $199.00/year

    The complete evidence behind every finding in every specialty, while your decision is live.

    Take the full library
  • Most readers

    Lifetime · one payment

    Everything, for good

    $499.00 once

    $499.00 (one-time)

    Every finding we publish today and hereafter — no renewal, no expiry. The tier we point most readers to.

    Take lifetime access

Prefer to pay per report? A single report is $29.00, yours to keep — browse the reports. The verdict is always free.

Where to go from here · Injectable Aesthetics Quality

no scope is a dead end — step up to the specialty, drill into a factor, or pivot across to a country or a comparison